Background illustration for clinical trials search

Paid Clinical Trials Ogden

Discover 1,071 paid clinical trials in Ogden, Utah. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,071

FeaturedActive & Responsive

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

for

Influenza

Location: West Jordan UT, Idaho Falls ID, Las Vegas NV,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 0 - 11

Code: NCT06094010

Phase3, Recruiting

Featured

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis,

Location: Ogden UT, Littleton CO, Las Vegas NV, Albuquerque NM,

Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06318169

Phase3, Recruiting

Featured

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for

Non-Small Cell Lung Cancer

Location: Ogden UT, Reno NV, Spokane WA, Chandler AZ,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06568939

Phase2, Recruiting

Featured

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

for

Chronic Migraine

Location: Clinton UT, Bountiful UT, Salt Lake City UT, Fresno CA,

Sponsor: AbbVie

Sex: All

Age: 12 - 17

Code: NCT06810505

Phase3, Recruiting

Featured

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

for

Episodic Migraine

Location: Clinton UT, Bountiful UT, Salt Lake City UT,

Sponsor: AbbVie

Sex: All

Age: 6 - 17

Code: NCT05711394

Phase3, Recruiting

Featured

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

for

Migraine

Location: Bountiful UT, Salt Lake City UT, Meridian ID, Aurora CO,

Sponsor: AbbVie

Sex: All

Age: 6 - 17

Code: NCT05125302

Phase3, Recruiting

Featured

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

for

Depression, Bipolar I Disorder

Location: Bountiful UT, Sacramento CA, Redlands CA, Chino CA,

Sponsor: AbbVie

Sex: All

Age: 10 - 17

Code: NCT04777357

Phase3, Recruiting

Featured

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

for

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Location: Salt Lake City UT, Rochester MN, Columbus OH

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05091424

Phase1, Recruiting

Featured

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

for

Non Small Cell Lung Carcinoma

Location: Salt Lake City UT, Aurora CO, Lone Tree CO,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06772623

Phase1, Phase2, Recruiting

Featured

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

for

Multiple Myeloma

Location: Salt Lake City UT, Los Angeles CA, Portland OR,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06953960

Phase1, Phase2, Recruiting

Paid Clinical Trials Ogden

Filter results

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Interested in new trials?

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)